Jennifer L. Taubert - 12 Feb 2024 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, WWC. Innovative Medicine
Signature
/s/ Raavi K. Deol, as attorney-in-fact for Jennifer Taubert
Issuer symbol
JNJ
Transactions as of
12 Feb 2024
Net transactions value
-$2,109,632
Form type
4
Filing time
14 Feb 2024, 18:36:31 UTC
Previous filing
12 Feb 2024
Next filing
15 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $0 +22,433 +16% $0.000000 163,849 12 Feb 2024 Direct F1
transaction JNJ Common Stock Options Exercise $0 +3,769 +2.3% $0.000000 167,618 12 Feb 2024 Direct F2
transaction JNJ Common Stock Tax liability $2,109,632 -13,403 -8% $157.40 154,215 12 Feb 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Performance Share Units Options Exercise $0 -22,433 -100% $0.000000* 0 12 Feb 2024 Common Stock 22,433 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Awarded under Issuer's Long-Term Incentive Plan. Performance Share Units awarded on February 8, 2021; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board on February 12, 2024.
F2 Shares earned due to performance factor of 116.8% upon certification of performance results by the Board.
F3 Shares withheld for payment of taxes upon vesting of Performance Share Units and certification of performance results by the Board.